Fig. 3

Percentage of patients achieved HbA1c < 7% /53 mmol/mol over time. For drug efficacy compared at 24 weeks’ time-point, reduction in mean HbA1c was significant in both groups, but the overall effect in reducing glycemic levels from baseline was significantly higher in Group A as compared to Group B (total effect difference: 0.91 ± 0.15 vs. 0.79 ± 0.14) (Fig. 3). A higher proportion of participants reached HbA1c < 7% (53 mmol/mol) at the 2nd and 3rd follow-up time point in Group A compared to Group B (41.7 and 28.1% vs. 35.7 31%, respectively. However, the HbA1c reduction is similar in both groups